Key result
Platelet glycoprotein IIb/IIIa receptor antagonists show promise in reducing complications of coronary angioplasty and acute coronary syndromes.
Why the study?
Do platelet glycoprotein IIb/IIIa receptor inhibitors reduce complications in patients with ischemic heart disease undergoing coronary angioplasty or with acute coronary syndromes?
Do platelet glycoprotein IIb/IIIa receptor inhibitors reduce complications in patients with ischemic heart disease undergoing coronary angioplasty or with acute coronary syndromes?
Platelet glycoprotein IIb/IIIa receptor antagonists are promising antiplatelet agents for reducing complications in ischemic heart disease.
The platelet glycoprotein (GP) IIb/IIIa receptor antagonists are powerful new antiplatelet drugs that show promise in reducing complications of coronary angioplasty and acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
VIDT et al. (1996) studied this question. Platelet glycoprotein IIb/IIIa receptor antagonists show promise in reducing complications of coronary angioplasty and acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: